Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep announced positive Phase I interim data for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The study met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers, with statistically significant pharmacodynamic activity at 7 mg/kg dose. The results support further clinical investigation in autoimmune indications such as rheumatoid arthritis.